Measuring kynurenine in the blood of pregnant women with and without chronic kidney disease
Compares blood kynurenine levels during pregnancy in women with and without chronic kidney disease.
Key facts
- Who runs it
- CHU de Reims
- Where
- Reims, FranceSee the site
- Trial code
- Registry title
- Kynurenine Concentrations During Pregnancy in Women With or Without Chronic Kidney Disease - A Prospective Multicenter Study
- Status
- Not yet recruiting
- People taking part
- 204 people, planned
- Started
- Mar 2026
- Expected to end
- May 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Blood sampling
- Record updated
- 17 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women in early pregnancy, with or without long-term kidney disease. Blood samples will track kynurenine levels during pregnancy.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Pregnant women with chronic kidney disease stage 2-4 (eGFR 15-89 mL/min/1.73m², diagnosed before pregnancy), or pregnant women without kidney disease
Main reasons for not taking part
- Twin or other multiple pregnancy
- Kidney transplantation
- Persons under guardianship or legal protection
This trial only enrols pregnant participants. The registry sentence this rests on: Adult pregnant women <14 weeks of amenorrhea
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult pregnant women <14 weeks of amenorrhea
- With or without CKD stage 2-4 (eGFR 15-89 mL/min/1.73m², diagnosed before pregnancy)
- Written informed consent
- Affiliation to a social security system
Who cannot take part
- Kidney transplantation
- Multiple pregnancy
- Persons under guardianship or legal protection
Where in France
- Marie MULLERReims, FranceContact: Vincent DUPONTNo longer taking part
About the trial
What the trial wants to find out
Chronic kidney disease (CKD) affects more than 10% of the population worldwide and represents the second most important risk factor for preeclampsia, a life-threatening complication of pregnancy responsible for approximately 80,000 maternal and 500,000 perinatal deaths each year. Experimental studies have suggested a causal link between CKD, relative kynurenine deficiency during pregnancy, and preeclampsia development. Kynurenine, a tryptophan metabolite, plays a central role at the materno-fetal interface, supporting placental energy production, maternal-fetal immune tolerance, and placental perfusion. This study will prospectively assess and compare longitudinal kynurenine concentrations in pregnant women with and without CKD, and evaluate their associations with maternal and fetal outcomes.
The 2 groups in the trial
- Women with chronic kidney diseaseOther group
Treatment: Blood sampling
- Women without chronic kidney diseaseOther group
Treatment: Blood sampling
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Concentrations of Kynurenine During Pregnancy in Women With or Without Chronic Kidney Disease: A Prospective Multicenter Study
- Plain-language title
- Measuring kynurenine in the blood of pregnant women with and without chronic kidney diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 February 2026